This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Oct 2017

Cerbios-Pharma boosts ADC bioconjugation service

Cerbios expanded its ADCs and Bioconjugation capabilities to accomodate increasing technological and market demand. Building further capacities on top of the already solid platform provided by the Proveo Alliance, Cerbios is keeping ahead of the technological advances and is able to offer a tailored experience in novel payloads and ADC scaffolds.

Cerbios further expanded its cytotoxic bioconjugation services for ADCs to accommodate the increasing market demand. 
The technological platform provided by Cerbios is now enforced with increased capabilities in handling state-of-the-art ADC scaffolds and extensive experience in manufacturing and conjugation of novel payloads classes (e.g. PBDs).
A partnership network with key process solution providers keeps Cerbios abreast of the innovation in large-scale ADCs manufacturing.
Cerbios is set for early stage support of ADCs development to accelerate time-to-clinical and time-to-market as well as processes scale-up in its cGMP environment.
Visit us during the CPhI Worldwide in Frankfurt (Hall 6.1, Booth B52) to gather information about Cerbios capabilities in process development, manufacture of cytotoxic drug-linker payloads and ADC Bioconjugation.

Mentioned Companies
Cerbios-Pharma SA
View company profile